| Primary |
| Unevaluable Event |
34.8% |
| Drug Use For Unknown Indication |
19.8% |
| Diabetes Mellitus |
11.0% |
| Type 2 Diabetes Mellitus |
10.6% |
| Hypertension |
6.6% |
| Erysipelas |
2.6% |
| Device Related Infection |
1.8% |
| Bladder Cancer |
1.3% |
| Product Used For Unknown Indication |
1.3% |
| Transient Ischaemic Attack |
1.3% |
| Atrial Fibrillation |
0.9% |
| Calcium Deficiency |
0.9% |
| Cardiovascular Event Prophylaxis |
0.9% |
| Gastrooesophageal Reflux Disease |
0.9% |
| Glaucoma |
0.9% |
| Hemiplegia |
0.9% |
| Hypercholesterolaemia |
0.9% |
| Hypoglycaemia |
0.9% |
| Ischaemic Cardiomyopathy |
0.9% |
| Myocardial Ischaemia |
0.9% |
|
| Infarction |
10.0% |
| Vomiting |
10.0% |
| Agranulocytosis |
7.5% |
| Pruritus |
7.5% |
| Acute Generalised Exanthematous Pustulosis |
5.0% |
| Cytolytic Hepatitis |
5.0% |
| Face Oedema |
5.0% |
| Hyperammonaemia |
5.0% |
| Hypoglycaemia |
5.0% |
| Hypoglycaemic Coma |
5.0% |
| Hypomagnesaemia |
5.0% |
| Rash Papular |
5.0% |
| Subdural Haematoma |
5.0% |
| Therapeutic Agent Toxicity |
5.0% |
| Anaemia |
2.5% |
| Exposure During Pregnancy |
2.5% |
| Hyponatraemia |
2.5% |
| Intestinal Obstruction |
2.5% |
| Malaise |
2.5% |
| Myocardial Infarction |
2.5% |
|
| Secondary |
| Type 2 Diabetes Mellitus |
20.0% |
| Diabetes Mellitus |
16.6% |
| Hypertension |
12.4% |
| Product Used For Unknown Indication |
9.7% |
| Drug Use For Unknown Indication |
6.9% |
| Depression |
4.1% |
| Fungal Skin Infection |
4.1% |
| Hypercholesterolaemia |
4.1% |
| Diabetes Mellitus Inadequate Control |
3.4% |
| Glaucoma |
2.8% |
| Diabetes Mellitus Non-insulin-dependent |
2.1% |
| Fungal Infection |
2.1% |
| Pruritus |
2.1% |
| Bladder Cancer |
1.4% |
| Bronchopneumonia |
1.4% |
| Dyslipidaemia |
1.4% |
| Essential Hypertension |
1.4% |
| Gout |
1.4% |
| Paronychia |
1.4% |
| Transient Ischaemic Attack |
1.4% |
|
| Vomiting |
12.9% |
| Weight Decreased |
9.7% |
| Anaemia |
6.5% |
| Pleural Mesothelioma |
6.5% |
| Stevens-johnson Syndrome |
6.5% |
| Tachycardia |
6.5% |
| Thrombocytopenia |
6.5% |
| Weight Increased |
6.5% |
| Acute Generalised Exanthematous Pustulosis |
3.2% |
| Blood Pressure Increased |
3.2% |
| Cytolytic Hepatitis |
3.2% |
| Diarrhoea |
3.2% |
| Disorientation |
3.2% |
| Exposure During Pregnancy |
3.2% |
| Face Oedema |
3.2% |
| Hepatitis |
3.2% |
| Hyperammonaemia |
3.2% |
| Hypoglycaemia |
3.2% |
| Hyponatraemia |
3.2% |
| Liver Disorder |
3.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
29.2% |
| Product Used For Unknown Indication |
15.0% |
| Type 2 Diabetes Mellitus |
12.8% |
| Diabetes Mellitus |
7.6% |
| Hypertension |
7.3% |
| Thrombosis Prophylaxis |
4.5% |
| Ill-defined Disorder |
2.7% |
| Pain |
2.6% |
| Diabetes Mellitus Non-insulin-dependent |
2.1% |
| Hiv Infection |
2.1% |
| Hypercholesterolaemia |
2.0% |
| Anxiety |
1.8% |
| Atrial Fibrillation |
1.7% |
| Depression |
1.7% |
| Hepatitis C |
1.5% |
| Chronic Lymphocytic Leukaemia |
1.4% |
| Prophylaxis |
1.2% |
| Essential Hypertension |
1.1% |
| Phlebitis |
1.1% |
| Arrhythmia |
0.9% |
|
| Renal Failure Acute |
14.2% |
| Weight Decreased |
7.5% |
| Renal Failure |
6.6% |
| Vomiting |
6.6% |
| Septic Shock |
5.7% |
| Thrombocytopenia |
5.7% |
| Urinary Retention |
5.7% |
| Weight Increased |
5.7% |
| Pulmonary Embolism |
4.7% |
| Somnolence |
4.7% |
| Sternal Fracture |
4.7% |
| Urinary Tract Infection |
4.7% |
| Respiratory Distress |
3.8% |
| Hepatitis |
2.8% |
| Hyponatraemia |
2.8% |
| Lactic Acidosis |
2.8% |
| Rhabdomyolysis |
2.8% |
| Toxic Skin Eruption |
2.8% |
| Transient Ischaemic Attack |
2.8% |
| Ventricular Fibrillation |
2.8% |
|
| Interacting |
| Cardiac Failure |
30.8% |
| Hypertension |
23.1% |
| Type 2 Diabetes Mellitus |
23.1% |
| Anxiety |
7.7% |
| Hypercholesterolaemia |
7.7% |
| Insomnia |
7.7% |
|
|
